DGAP-News: HAEMATO AG
/ Key word(s): Interim Report
HAEMATO AG publishes figures for Q2 2022: increase in revenues and EBIT compared to the previous quarter; confirmation of guidance for the full year 2022
Berlin, 17. August 2022 – HAEMATO AG (ISIN: DE000289VV1) increased its revenue in the second quarter of 2022 by EUR 11.9 million compared to the first quarter of 2022 to EUR 66.4 million. The operating result (EBIT) increased from EUR 2.0 million to EUR 2.4 million in this period.
For the first half of 2022, the consolidated Group turnover (according to IFRS) amounts to EUR 121.0 million. The turnover of the previous year's period (1st January to 30th June 2021) still included contracts before the initiated portfolio adjustment as well as one-time special effects from the Corona test business, which could not be repeated in this form in the current financial year. Compared to the first half of 2020, turnover was increased by 4.5%.
The result from ordinary activities (EBITDA) for the first half of 2022 is EUR 5.1 million (previous year EUR 8.0 million). The operating result (EBIT) amounts to EUR 4.4 million (previous year EUR 7.2 million). Compared to the first half of 2020, EBIT has more than tripled.
"We are continuing on a good path of gradually improving our EBIT margin through consistent product management and implementation of the efficiency improvement programmes. Compared to the 2020 financial year, with an EBIT margin was 0.7%, we were able to increase and stabilise the EBIT margin in the first half of 2022 to 3.6%. We are thus moving towards the margin of 3.9% from the 2021 financial year, which was particularly influenced by the lucrative Corona test business," says Patrick Brenske, CEO of HAEMATO AG.
The new segment "Lifestyle & Aesthetics" contributed disproportionately to the result and will be further expanded in the future. Preparations for the approval of a proprietary botulinum toxin for the European market are proceeding according to plan.
Equity increased from EUR 144.7 million as of 31 December 2021 to EUR 145.6 million as of 30 June 2022. The equity ratio has increased from 79.5% to 84.6% and illustrates the healthy capital structure of the group.
The company confirms its guidance for the 2022 financial year and continues to expect EBIT of EUR 8 to 10 million.
The half-year results and further information will be published in the interim report for the first half of the year on 25 August 2022.
HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on trading in high-priced specialty pharmaceutical drugs (with a therapeutic focus on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of "Lifestyle & Aesthetics". HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information can be found at https://haemato.de.Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
17.08.2022 CET/CEST Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Phone:||+49 (0)30 897 30 86 70|
|Fax:||+49 (0)30 897 30 86 79|
|Listed:||Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange|
|EQS News ID:||1421949|
|End of News||DGAP News Service|
1421949 17.08.2022 CET/CEST